Cited by 1,858HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 65 of the 70 references it cites were found in a registry or an index.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Open access

Nagata, Yoichi, Lan, Keng-Hsueh, Zhou, Xiaoyan, Tan, Ming, Esteva, Francisco J., Sahin, Aysegul A., Klos, Kristine S., Li, Ping, Monia, Brett P., Nguyen, Nina T., Hortobagyi, Gabriel N., Hung, Mien-Chie, Yu, Dihua·2004·Cancer Cell

DOI 10.1016/j.ccr.2004.06.022

Open this paper in CoChat — free account Open PDF

Abstract

The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate, however, is limited and what determines trastuzumab response is poorly understood. Here we report that PTEN activation contributes to trastuzumab's antitumor activity. Trastuzumab treatment quickly increased PTEN membrane localization and phosphatase activity by reducing PTEN tyrosine phosphorylation via Src inhibition. Reducing PTEN in breast cancer cells by antisense oligonucleotides conferred trastuzumab resistance in vitro and in vivo. Patients with PTEN-deficient breast cancers had significantly poorer responses to trastuzumab-based therapy than those with normal PTEN. Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2004.06.022

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,018
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,637
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

Show all 70 references

Research works printed but not linked: 1

Petit, 1997, Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo, Am. J. Pathol., 151, 1523

Sorted by citations

Items 901–1,000 of 1,001

Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
Acevedo-Gadea, C. R., Hatzis, C., Chung, G. G., Fischbach, N. A., Lezon-Geyda, K., Zelterman, D. A., DiGiovanna, M. P., Harris, L. N., & Abu-Khalaf, M. M. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3292-8 · Cited by 28
Downregulation of miroRNA‐141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4
Han, G., Qiu, N., Luo, K., Liang, H., & Li, H. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28416 · Cited by 29
Targeted Antireceptor Therapy with Monoclonal Antibodies Leads to the Formation of Inactivated Tetrameric Forms of ErbB Receptors
Furuuchi, K., Berezov, A., Kumagai, T., & Greene, M. I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.1021 · Cited by 28
Genomics and proteomics—the way forward
Baak, J. P. A., Janssen, E. A. M., Søreide, K., & Heikkilæ, R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi728 · Cited by 30
Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT–mTOR pathway
Deng, M., Wang, J., Chen, Y., Zhang, L., & Liu, D. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000202 · Cited by 27
Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway
Weickhardt, A. J., Tebbutt, N. C., & Mariadason, J. M. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357961 · Cited by 27
Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer
Ishida, M., Kagawa, S., Shimoyama, K., Takehara, K., Noma, K., Tanabe, S., Shirakawa, Y., Tazawa, H., Kobayashi, H., & Fujiwara, T. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0644 · Cited by 27
Novel treatment strategies for patients with HER2‑positive breast cancer who do not benefit from current targeted therapy drugs (Review)
Jiang, N., Lin, J., Wang, J., Zhang, B., Li, A., Chen, Z., Guo, S., Li, B., Duan, Y., Yan, R., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6459 · Cited by 27
TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells
Dı́az-Rodrı́guez, E., Pérez‐Peña, J., Ríos‐Luci, C., Arribas, J., Ocaña, A., & Pandiella, A. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.042 · Cited by 26
Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
Doi, T., Fujiwara, Y., Matsubara, N., Tomomatsu, J., Iwasa, S., Tanaka, A., Endo-Tsukude, C., Nakagawa, S., & Takahashi, S. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03882-7 · Cited by 28
The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.
Malaguti, P., Vari, S., Cognetti, F., & Fabi, A. (2013) · PubMed · Cited by 27
Prognostic significance and targeting of HER family in colorectal cancer
Modjtahedi, H. (2012) · Frontiers in bioscience · doi:10.2741/4110 · Cited by 27
Trastuzumab resistance: all roads lead to SRC
Muthuswamy, S. K. (2011) · Nature Medicine · doi:10.1038/nm0411-416 · Cited by 27
A biosensor to monitor dynamic regulation and function of tumour suppressor PTEN in living cells
Lima‐Fernandes, E., Misticone, S., Boularan, C., Paradis, J. S., Enslen, H., Roux, P. P., Bouvier, M., Baillie, G. S., Marullo, S., & Scott, M. G. H. (2014) · Nature Communications · doi:10.1038/ncomms5431 · Cited by 27
Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells
Yoshida, R., Tazawa, H., Hashimoto, Y., Yano, S., Onishi, T., Sasaki, T., Shirakawa, Y., Kishimoto, H., Uno, F., Nishizaki, M., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1249-x · Cited by 27
Cancer Systems Biology
Faratian, D., Bown, J., Smith, V. A., Langdon, S. P., & Harrison, D. J. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-800-3_12 · Cited by 27
Clinical outcomes based on multigene profiling in metastatic breast cancer patients
Basho, R. K., Gagliato, D. D. M., Ueno, N. T., Wathoo, C., Chen, H., Shariati, M., Wei, C., Álvarez, R. H., Moulder, S. L., Şahin, A. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12987 · Cited by 27
Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Hormonal Therapy for the Treatment of Primary HER2-Positive Breast Cancer: One More Step Toward Chemotherapy-Free Therapy
Prat, A., & Baselga, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4998 · Cited by 27
Signaling pathway dysregulation in breast cancer
Ryspayeva, D., Seyhan, A. A., MacDonald, W., Purcell, C., Roady, T. J., Ghandali, M., Verovkina, N., El‐Deiry, W. S., Taylor, M. S., & Graff, S. L. (2025) · Oncotarget · doi:10.18632/oncotarget.28701 · Cited by 31
Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer
Huang, Y., Fu, P., & Fan, W. (2013) · Current Drug Targets · doi:10.2174/13894501113149990161 · Cited by 26
[Molecular classification of breast cancer].
Zepeda-Castilla, E., Recinos-Money, E., Cuéllar-Hübbe, M., Robles-Vidal, C. D., & Maafs-Molina, E. (2008) · PubMed · Cited by 26
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells
Canonici, A., Qadir, Z., Conlon, N. T., Collins, D. M., O’Brien, N. A., Walsh, N., Eustace, A. J., O’Donovan, N., & Crown, J. P. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0556-7 · Cited by 26
HetRCNA: A Novel Method to Identify Recurrent Copy Number Alternations from Heterogeneous Tumor Samples Based on Matrix Decomposition Framework
Xi, J., Li, A., & Wang, M. (2018) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2018.2846599 · Cited by 26
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N. T., Raghavendra, A. S., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01665-w · Cited by 29
Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis
Zhang, Q., Chen, J., 俞晓立, Cai, G., 杨兆知, Cao, L., Hu, C., 郭小毛, Sun, J., & Chen, J. (2015) · Breast Cancer · doi:10.1007/s12282-015-0631-x · Cited by 26
Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
Shor, B., Kahler, J., Dougher, M. M., Xu, J. J., Mack, M. L., Rosfjord, E. C., Wang, F., Melamud, E., & Sapra, P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1166 · Cited by 28
Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer
Rugo, H. S. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.09.004 · Cited by 27
Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging
Smith, T. (2010) · British Journal of Radiology · doi:10.1259/bjr/31053812 · Cited by 26
Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3
Young, C. D., Nolte, E. C., Lewis, A. S., Serkova, N. J., & Anderson, S. M. (2008) · Breast Cancer Research · doi:10.1186/bcr2132 · Cited by 26
Estrogen receptor α induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells
Kim (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.412 · Cited by 26
Solenopsin A and analogs exhibit ceramide-like biological activity
Karlsson, I. B., Zhou, X., Thomas, R. J., Smith, A. T., Bonner, M. Y., Bakshi, P., Banga, A. K., Bowen, J. P., Qabaja, G., Ford, S. L., et al. (2015) · Vascular Cell · doi:10.1186/s13221-015-0030-2 · Cited by 26
Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women
Khan, F. A., Esnakula, A. K., Ricks‐Santi, L. J., Zafar, R., KANAAN, Y. M., & Naab, T. J. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.03.020 · Cited by 26
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway
Crowder, R. J., & Ellis, M. J. (2005) · Breast Cancer Research · doi:10.1186/bcr1307 · Cited by 26
Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents
Holash, J. A., Thurston, G., Rudge, J. S., Yancopoulos, G. D., Adjei, A. A., Bergers, G., Pytowski, B., Pegram, M. D., & Gordon, M. S. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-8504-6 · Cited by 26
Inhibition of ErbB2 by Herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line
Dogan, I., Cumaoğlu, A., Aricioglu, A., & Ekmekçi, A. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0610-7 · Cited by 28
Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance
Nahta, R. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/648965 · Cited by 25
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
Ocaña, A., Gil-Martín, M., Martín, M., Rojo, F., Antolín, S., Guerrero, Á., Trigo, J. M., Muñoz-Mateu, M., Pandiella, A., Gonzalo, N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17113 · Cited by 25
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
Filipits, M., Dafni, U. G., Gnant, M., Polydoropoulou, V., Hills, M., Kiermaier, A. C., de Azambuja, E., Larsimont, D., Rojo, F., Viale, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3473 · Cited by 25
Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines
Gürdal, H., Tuglu, M., Bostanabad, S. Y., & ⁄, B. D. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4697 · Cited by 25
Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance
Hwang, S., Choi, S.-K., Seo, S. H., Jo, H., Shin, J. H., Na, Y., Lee, Y., & Kwon, Y. (2020) · Cancers · doi:10.3390/cancers12061540 · Cited by 25
HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models
Gameiro, A., Nascimento, C., Correia, J., & Ferreira, F. (2021) · Cancers · doi:10.3390/cancers13092007 · Cited by 28
The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective
Fogazzi, V., Kapahnke, M., Cataldo, A., Plantamura, I., Tagliabue, E., Cosimo, S. D., Cosentino, G., & Iorio, M. V. (2022) · Cancers · doi:10.3390/cancers14215326 · Cited by 25
Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field.
Ledda, F., & Paratcha, G. (2007) · PubMed Central · Cited by 25
Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma.
Ramieri, M. T., Murari, R., Botti, C., Pica, E., Zotti, G., & Alò, P. L. (2010) · PubMed · Cited by 25
Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients
Tessari, A., Cosimo, S. D., & Palmieri, D. (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s53304 · Cited by 26
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy
McCubrey, J. A., Sokolosky, M. L., Lehmann, B. D., Taylor, J. R., Navolanic, P. M., Chappell, W. H., Abrams, S. L., Stadelman, K. M., Wong, E. W. T., Misaghian, N., et al. (2008) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2008.02.006 · Cited by 25
Treatment of HER2-Positive Metastatic Breast Cancer Following Initial Progression
Mayer, I. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.005 · Cited by 25
New targeted therapies for gastric cancer
Asaoka, Y., Ikenoue, T., & Koike, K. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.566863 · Cited by 25
Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer
Koo, D., Lee, H. J., Ahn, J. H., Yoon, D. H., Kim, S., Gong, G., Son, B. H., Ahn, S. H., & Jung, K. H. (2015) · Tumor Biology · doi:10.1007/s13277-015-3258-9 · Cited by 25
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy
Fujimoto-Ouchi, K., Sekiguchi, F., Yamamoto, K., Shirane, M., Yamashita, Y., & Mori, K. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1160-0 · Cited by 25
The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced Breast Cancer
Gnant, M. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0277-1 · Cited by 25
Target Points in Trastuzumab Resistance
Shojaei, S., Gardaneh, M., & Shamabadi, A. R. (2012) · International Journal of Breast Cancer · doi:10.1155/2012/761917 · Cited by 25
Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody
Wang, S., Chen, C., Meng, Y., Hu, S., Zheng, L., Song, J., Zhang, D., Li, B., & Guo, Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.07.007 · Cited by 25
Effects of Simultaneous Knockdown of HER2 and PTK6 on Malignancy and Tumor Progression in Human Breast Cancer Cells
Ludyga, N., Anastasov, N., Rosemann, M., Seiler, J., Lohmann, N., Braselmann, H., Mengele, K., Schmitt, M., Höfler, H., & Aubele, M. M. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0378 · Cited by 25
Buparlisib in breast cancer.
Sirohi, B., Rastogi, S., & Dawood, S. (2015) · Future Oncology · doi:10.2217/fon.15.56 · Cited by 26
Breast cancer suppression by aplysin is associated with inhibition of PI3K/AKT/FOXO3a pathway
Zhang, X., Zhuang, T., Liang, Z., Li, L., Xue, M., Liu, J., & Liang, H. W. (2017) · Oncotarget · doi:10.18632/oncotarget.19209 · Cited by 26
Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
Ito, Y., Tokudome, N., Sugihara, T., Takahashi, S., & Hatake, K. (2007) · Breast Cancer · doi:10.2325/jbcs.971 · Cited by 25
Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods
Nakajima, H., Mizuta, N., Sakaguchi, K., Fujiwara, I., Yoshimori, A., Takahashi, S., Takasawa, R., & Tanuma, S.-I. (2007) · Breast Cancer · doi:10.1007/s12282-007-0018-8 · Cited by 25
Expression of NRG1 and its receptors in human bladder cancer
Forster, J. A., Paul, A., Harnden, P., & Knowles, M. A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.39 · Cited by 24
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy
Yamashita, S., Hattori, N., Fujii, S., Yamaguchi, T., Takahashi, M., Hozumi, Y., Kogawa, T., El‐Omar, O., Liu, Y.-Y., Arai, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72661-9 · Cited by 24
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer
Zou, H., Luo, J., Guo, Y., Deng, L., Zeng, L., Pan, Y., & Li, P. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101051 · Cited by 27
Intracellular antigens as targets for antibody based immunotherapy of malignant diseases
Wang, Y., Wang, X., Ferrone, C. R., Schwab, J. H., & Ferrone, S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.019 · Cited by 24
Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis
Khoury, T., Kanehira, K., Wang, D., Ademuyiwa, F. O., Mojica, W. D., Cheney, R., Morrison, C., Conroy, J. M., Nowak, N. J., & Liu, S. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.125 · Cited by 24
Inhibition of autophagy induced by PTEN loss promotes intrinsic breast cancer resistance to trastuzumab therapy
Liao, N., Guo-chun, Z., An, S., Li, X., Wang, K., Jian, Z., Chong-Yang, R., Wen, L., & Lv, H. (2015) · Tumor Biology · doi:10.1007/s13277-015-4392-0 · Cited by 24
Current Development of Monoclonal Antibodies in Cancer Therapy
Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 25
PTEN Loss-Mediated Akt Activation Increases the Properties of Cancer Stem-Like Cell Populations in Prostate Cancer
Kim, R., Bae, E., Hong, Y. K., Hong, J. Y., Kim, N. K., Ahn, H. J., Oh, J. J., & Park, D. S. (2014) · Oncology · doi:10.1159/000363186 · Cited by 24
Emerging treatment combinations: Integrating therapy into clinical practice
Wong, S. T.-L. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090439 · Cited by 24
Successful targeting of ErbB2 receptors—is PTEN the key?
Crowder, R. J., Lombardi, D. P., & Ellis, M. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.001 · Cited by 24
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02578-w · Cited by 23
Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
Campone, M., Juin, P. P., André, F., & Bachelot, T. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.04.012 · Cited by 23
Molecular mechanisms and clinical implications of miRNAs in drug resistance of colorectal cancer
Duan, L., Yang, W., Feng, W., Cao, L., Wang, X., Niu, L., Li, Y., Zhou, W. J., Zhang, Y., Liu, J., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920947342 · Cited by 24
Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
Mata, J. J., Rebollo-Liceaga, J., Martinez-Navarro, E., Manzano, R. G., Brugarolas, A., Juan, M., & Sureda, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.926289 · Cited by 23
Human papillomavirus‐stratified analysis of the prognostic role of mi R ‐21 in oral cavity and oropharyngeal squamous cell carcinoma
Ko, Y. H., Won, H. S., Sun, D. S., An, H. J., Jeon, E. K., Kim, M., Lee, H. H., Kang, J. H., & Jung, C. K. (2014) · Pathology International · doi:10.1111/pin.12201 · Cited by 23
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Cheng, H., Bai, Y., Sikov, W. M., Sinclair, N. F., Bossuyt, V., Abu-Khalaf, M. M., Harris, L. N., & Rimm, D. L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-326 · Cited by 23
The epidermal growth factor receptor family in breast cancer
Koutras, A. K. (2008) · OncoTargets and Therapy · doi:10.2147/ott.s3842 · Cited by 24
Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition
Goltsov, A., Faratian, D., Langdon, S. P., Bown, J., Goryanin, I., & Harrison, D. J. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.011 · Cited by 24
Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer
Tanioka, M., Sakai, K., Sudo, T., Sakuma, T., Kajimoto, K., Hirokaga, K., Takao, S., Negoro, S., Minami, H., Nakagawa, K., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3121-5 · Cited by 23
Pertuzumab: A New Targeted Therapy for HER 2‐Positive Metastatic Breast Cancer
Malenfant, S. J., Eckmann, K. R., & Barnett, C. M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1338 · Cited by 23
Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
Guiu, S., Mouret‐Reynier, M., Touré, M., & Coudert, B. P. (2013) · Journal of Oncology · doi:10.1155/2013/854121 · Cited by 23
Ovarian Epithelial Cancer Stem Cells
Conić, I., Dimov, I., Tasic-Dimov, D., Djordjević, B., & Stefanović, V. (2011) · The Scientific World JOURNAL · doi:10.1100/tsw.2011.112 · Cited by 22
Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer
Chergui, F., Chrétien, A.-S., Bouali, S., Ramacci, C., Rouyer, M., Bastogne, T., Génin, P., Leroux, A., & Merlin, J. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.116632 · Cited by 23
Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody
Yu, X., Wang, L., Shen, Y., Wang, C., Zhang, Y., Meng, Y., Yang, Y., Liang, B., Zhou, B., Wang, H., et al. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.05.010 · Cited by 23
The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy
Gámez‐Pozo, A., Carrión, R. M. P., Manso, L., Crespo, C., Mendiola, C., López‐Vacas, R., Berges‐Soria, J., Álvarez, I., Vila, M. M., Calero, J. L. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109611 · Cited by 24
Breast cancer: Molecular basis and therapeutic strategies (Review)
Ligresti, G., Libra, M., Militello, L., Clementi, S., Donia, M., Imbesi, R., Malaponte, G., Cappellani, A., McCubrey, J. A., & Stivala, F. (2008) · Molecular Medicine Reports · doi:10.3892/mmr.1.4.451 · Cited by 23
Tumor-Associated Antigens and Biomarkers in Cancer and Immune Therapy
Malyankar, U. M. (2007) · International Reviews of Immunology · doi:10.1080/08830180701402496 · Cited by 23
Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
Vogel, C., Chan, A., Gril, B., Kim, S.-B., Kurebayashi, J., Liu, L., Lu, Y., & Moon, H. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq084 · Cited by 23
Why targeted therapy hasn’t worked in advanced cancer
Arbiser, J. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33190 · Cited by 22
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer
Momeny, M., Tienhaara, M., Sharma, M., Chakroborty, D., Varjus, R., Takala, I., Merisaari, J., Padzik, A., Vogt, A., Paatero, I., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00088-0 · Cited by 24
Genomic Markers of Resistance to Targeted Treatments in Gastric Cancer: Potential New Treatment Strategies
Raimondi, A., Nichetti, F., Peverelli, G., Bartolomeo, M. D., de Braud, F., & Pietrantonio, F. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0077 · Cited by 22
Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation
Virzì, A., Gentile, A., Benvenuti, S., & Comoglio, P. (2018) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1721147115 · Cited by 19
Aberrant Upregulation of Indoleamine 2,3-Dioxygenase 1 Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Cells via Coordinated Activation of AhR and β-Catenin Signaling
Chen, C.-T., Wu, P., Hu, C.-C., Nien, H., Wang, J., Sheu, J., & Chow, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111661 · Cited by 22
Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process
Deb, T. B., Zuo, A., Barndt, R. J., Sengupta, S., Janković, R., & Johnson, M. D. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3337-z · Cited by 22
The evolving landscape of protein kinases in breast cancer: Clinical implications
Ocaña, A., Amir, E., Šeruga, B., Martín, M., & Pandiella, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.05.004 · Cited by 22
Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance
Liu, D., Shi, M., Duan, C., Chen, H., Hu, Y., Yang, Z., Duan, H., & Guo, N. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.04.007 · Cited by 22
Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.
Cara, G. D., Marengo, G., Albanese, N. N., Marabeti, M. R., Musso, R., Cancemi, P., & Pucci‐Minafra, I. (2013) · PubMed · Cited by 22
PIK3CA/AKT1 Mutations in Breast Carcinoma: a Comprehensive Review of Experimental and Clinical Studies
Troxell, M. L. (2012) · Journal of Clinical & Experimental Pathology · doi:10.4172/2161-0681.s1-002 · Cited by 24
Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer
Phelps-Polirer, K., Abt, M. A., Smith, D. M., & Yeh, E. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153025 · Cited by 22
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Taveira, M. D. O., Nabavi, S., Wang, Y.-K., Tonellato, P. J., Esteva, F. J., Cantley, L. C., & Wulf, G. M. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2358-x · Cited by 22
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer
Agahozo, M. C., Sieuwerts, A. M., Doebar, S. C., Verhoef, E. I., Beaufort, C. M., Ruigrok-Ritstier, K., de Weerd, V., Sleddens, H. F. B. M., Dinjens, W. N. M., Martens, J. W. M., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0019 · Cited by 22
Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
Garay, T., Kenessey, I., Molnár, E., Juhász, É., Réti, A., László, V., Rózsás, A., Dobos, J., Döme, B., Berger, W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117021 · Cited by 22

Authors: Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., & Yu, D.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Ionis Pharmaceuticals (United States) (US)
Corresponding author: Yu, Dihua
ORCID: Lan, Keng-Hsueh
Zhou, Xiaoyan
Tan, Ming
Esteva, Francisco J.
Li, Ping
Monia, Brett P.
Hung, Mien-Chie
Yu, Dihua
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2004-08
Volume: 6
Issue: 2
Pages: 117-127
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2004.06.022
OpenAlex: W2059411043
Cited by: 1,858
References: 70
Citations by year: 2026: 19 · 2025: 29 · 2024: 35 · 2023: 82 · 2022: 52 · 2021: 50 · 2020: 60 · 2019: 56 · 2018: 66 · 2017: 68 · 2016: 88 · 2015: 109 · 2014: 119 · 2013: 125 · 2012: 123
FWCI: 43.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3272 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca060488-09)
National Cancer Institute (P01CA099031, 2R01-CA60488, P30CA016672)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: PTEN, trastuzumab, trastuzumab resistance, ERBB2, HER2-positive breast cancer, Src kinase inhibition, PI3K inhibitors, predictive biomarkers, antisense oligonucleotides
MeSH terms: Trastuzumab, Phosphoinositide-3 Kinase Inhibitors, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Enzyme Activation, Enzyme Inhibitors, Female, Humans, Mice, Nude, Neoplasm Transplantation, Phosphoric Monoester Hydrolases, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Oligonucleotides, Antisense, Protein Serine-Threonine Kinases, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, src-Family Kinases, Phosphatidylinositol 3-Kinases, Tumor Suppressor Proteins, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks